Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015. ,
The molecular landscape of head and neck cancer, Nat. Rev. Cancer, vol.18, pp.269-282, 2018. ,
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front, vol.7, p.72, 2017. ,
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N. Engl. J. Med, vol.354, pp.567-578, 2006. ,
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression, Cancer Cell, vol.5, pp.489-500, 2004. ,
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes, PLoS ONE, vol.8, 2013. ,
, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, vol.517, pp.576-582, 2015.
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes, Clin. Cancer Res, vol.21, pp.870-881, 2015. ,
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data, Oncotarget, vol.6, pp.9627-9642, 2015. ,
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab, Clin. Cancer Res, vol.22, pp.3961-3970, 2016. ,
Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-961, 2013. ,
Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance, Oncologist, vol.18, pp.850-864, 2013. ,
EGF receptor ligands: Recent advances, vol.5, 2016. ,
Epiregulin: Roles in normal physiology and cancer, Semin. Cell Dev. Biol, vol.28, pp.49-56, 2014. ,
Epiregulin as a therapeutic target in non-small-cell lung cancer, Lung Cancer, vol.6, pp.91-98, 2015. ,
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer, Tumour Biol. J. Int. Soc. Oncodev. Biol. Med, vol.37, pp.11645-11655, 2016. ,
Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?, Curr. Treat. Options Oncol, vol.18, 2017. ,
A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis, Clin. Cancer Res, vol.19, pp.4174-4184, 2013. ,
, Amphiregulin. Semin. Cell Dev. Biol, vol.28, pp.31-41, 2014.
Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, vol.483, pp.570-575, 2012. ,
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012. ,
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models, Br. J. Cancer, vol.110, pp.2887-2895, 2014. ,
Molecular target approaches in head and neck cancer: Epidermal growth factor receptor and beyond, Semin. Radiat. Oncol, vol.19, pp.63-68, 2009. ,
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck, J. Clin. Oncol, vol.22, pp.77-85, 2004. ,
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial, Lancet Oncol, vol.16, pp.583-594, 2015. ,
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial, J. Clin. Oncol, vol.31, pp.1415-1421, 2013. ,
Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma, Int. J. Cancer, vol.120, pp.781-787, 2007. ,
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy, Cancer Immunol. Immunother, vol.66, pp.573-579, 2017. ,
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer, Ann. Oncol, vol.28, pp.2526-2532, 2017. ,
Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry, BMC Cancer, vol.9, issue.6, 2009. ,
Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma, Clin. Cancer Res, vol.3, pp.3-9, 1997. ,
Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family, 2013. ,
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells, Clin. Cancer Res, vol.12, pp.4103-4111, 2006. ,
Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members, Oncogene, vol.27, pp.3944-3956, 2008. ,
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance, Clin. Cancer Res, vol.17, pp.5935-5944, 2011. ,
Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines, Int. J. Oncol, vol.40, pp.1805-1812, 2012. ,
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial, Lancet, vol.379, pp.633-640, 2012. ,
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70), Clin. Cancer Res, vol.21, pp.2924-2931, 2015. ,
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cell. Immunol, vol.319, pp.35-42, 2017. ,
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells, Oncol. Rep, vol.34, pp.2864-2870, 2015. ,
,
, IGBMC, UMR 7104 CNRS-UdS, U.1258 INSERM
, , 2019.
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells, Br. J. Cancer, vol.106, pp.1406-1414, 2012. ,
Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines, J. Cancer Res. Clin. Oncol, vol.138, pp.491-499, 2012. ,
EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines, J. Oral Pathol. Med, vol.42, pp.26-36, 2013. ,
Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients, Oncotarget, vol.7, pp.55890-55899, 2016. ,
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer, Br. J. Cancer, vol.110, pp.648-655, 2014. ,
Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab, Head Neck, vol.40, pp.2424-2431, 2018. ,
SynergyFinder: A web application for analyzing drug combination dose-response matrix data, Bioinformatics, vol.33, pp.2413-2415, 2017. ,